Editor's note: This article first appeared in the Apex360 newsletter. Not a subscriber? Go here to sign up for the latest industry updates delivered twice a week to your inbox. Apex360 is a member of the DentistryIQ.com network.
-----
EARTH CITY, MISSOURI -- Young Dental, a designer, manufacturer and marketer of consumables, instruments and other items used in the dental industry, today announced the acquisition of Oral-B Minute-Foam, Centrays and Centwins trays, and SUPA disposable prophy angles.
“This relationship will allow us to expand the premium product offering available to dental professionals under the Oral-B brand name,” said Dave Sproat, CEO of Young. “We look forward to bringing new and innovative products to market through this relationship, which is core to our long-term growth strategy.”
This transaction combines two widely recognized brands with expertise in dental products and strong customer relationships.
The acquisition and license does not apply to over-the-counter retail dental products, including but not limited to items like toothpaste, toothbrushes, floss and mouth rinse.
Young Dental is a wholly-owned subsidiary of Young Innovations, Inc., which is a portfolio company of Linden Capital Partners. Kirkland & Ellis LLP served as legal counsel to Young.
-----
Company info: Young Innovations, Inc.: Young develops, manufactures, and markets supplies and equipment used by dentists, dental hygienists, dental assistants and consumers.
The company’s consumables product offering includes disposable and metal prophy angles, prophy cups and brushes, dental micro-applicators, moisture control products, infection control products, dental handpieces (drills), and related components, endodontic systems, orthodontic toothbrushes, flavored examination gloves and other products.
In addition, the company offers a line of diagnostic products that includes panoramic X-ray machines and related supplies.
Company Info: Linden Capital Partners: Linden Capital Partners is Chicago-based private equity firm focused exclusively on leveraged buyouts in the healthcare and life sciences industries.
Linden’s strategy is based upon three elements: i) healthcare and life science industry specialization, ii) integrated private equity and operating expertise, and iii) strategic relationships with large corporations. Linden invests in middle market platforms in the medical products, specialty distribution, pharmaceutical, and services segments of healthcare.
-----
